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ishao@ucsd.edu (JAbstract White adipose tissue (WAT) is a key energy depot in humans and most animals.
Traditionally, it is believed that WAT passively accumulates triglycerides or releases fatty acids to
accommodate systemic energy metabolism. However, recent studies have demonstrated that WAT
also actively participates in energy metabolism mainly through its secretion of cytokines and
hormones. Therefore, at this time, WAT is recognized as an endocrine organ. Adiponectin is one of
the key adipocyte-derived hormones that regulate systemic or tissue lipid and glucose metabolism.
In contrast to most other adipocyte-derived hormones, adiponectin increases insulin sensitivity and
improves lipid and glucose metabolism. Although the insulin-sensitizing function of adiponectin
has been well established, recent studies have demonstrated that adiponectin also regulates
metabolism through pathways independent of insulin signaling. Due to the massive tissue mass
of skeletal muscle, lipid uptake and subsequent fatty acid oxidation in skeletal muscle have a big
impact on maintaining systemic energy homeostasis. Furthermore, adiponectin gene expression is
regulated by energy intake. Therefore, adiponectin serves as a coordinator of energy balance
amongst WAT, skeletal muscle and other tissues. We summarize the regulatory effects of
adiponectin on lipid and glucose metabolism in skeletal muscle. Future research directions have
also been proposed.
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Adiponectin is adipocyte-derived hormone with aprominent
function of increasing insulin sensitivity. Unlike other adipo-
kines, such as leptin and resistin, adiponectin gene expression
and circulating levels are inversely correlated with adiposity1,2.
Furthermore, a decrease in blood adiponectin levels in the
prediabetic state precedes the reduction in insulin sensitivity3,
suggesting hypoadiponectinemia may contribute to the
development of insulin resistance in obesity and type 2
diabetes3–6. Thus, in the past decade, tremendous efforts have
been committed to studying the roles and the underlying
mechanisms by which adiponectin improves energy metabo-
lism and insulin sensitivity. Increasing fatty acid oxidation
in skeletal muscle is one of the important mechanisms that
may be the basis of the insulin-sensitizing effect of adiponec-
tin7,8. Recent studies revealed that, independent of insulin
signaling, adiponectin enhances triglyceride (TG) catabolism,
fatty acid uptake, and mitochondrial biogenesis, which further
supports the importance of adiponectin in regulating lipid
metabolism in skeletal muscle. In this review, we will brieﬂy
summarize general backgrounds of adiponectin and discuss
the progress and detailed ﬁndings about the underlying
mechanism of adiponectin-improved lipid metabolism in
skeletal muscle.2. Adiponectin gene structure
The human adiponectin gene spans 16 kb in chromosome 3
and is composed of three exons from 18–4,277 bp in size with
consensus splice sites9–11. A basic promoter and an intronic
enhancer have been identiﬁed in the human adiponectin gene.
Similar to that of other adipocyte-derived hormones, adipo-
nectin gene transcription is under the control of adipocyte
master transcription factors including peroxisome proliferator-
activated receptors g (PPARg) and CCAAT enhancer binding
protein a (C/EBPa)12,13. Several other transcription factors
have been found to be able to bind adiponectin gene and
regulate its transcription14,15.
Adiponectin protein is composed of an N-terminal signal
sequence, a globular domain near the C terminus, and a
collagen-like domain16. The adiponectin is a 30 kD protein of
247 amino acids. During secretion, adiponectin forms several
different multimeric protein complexes in adipocytes17. The
basic structure is the trimer. Adiponectin trimers are able to
form higher-ordered complexes through the noncovalent
binding of two trimers (hexamers) and six trimers (18 mers).
Based on the migration speeds during electrophoresis, these
higher-ordered complexes are described as low molecular
weight (LMW, trimers), medium molecular weight (MMW,
hexamers) and high molecular weight (HMW, 12–18 mers)
forms of adiponectin11,18. While HMW forms comprise the
major forms of intracellular adiponectin, LMW forms com-
prise the major part of circulating adiponectin19. A study
suggested that blood HMW levels may be more closely
correlated with systemic insulin sensitivity when compared
with other multimeric adiponectin, and the ratio between
HMW and total adiponectin may be more precise than total
adiponectin for demonstrating the relationship between adi-
ponectin and insulin resistance20. However, which forms of
adiponectin are biologically active is still controversial19–21.3. Tissue expression pattern of adiponectin
Although the adiponectin gene was ﬁrst cloned and primarily
expressed in adipose tissue11, studies have reported that
adiponectin is also expressed in some non-adipose tissues
including central nervous system (CNS)22–25. By studying
adiponectin mRNA and protein, several peripheral tissues
have been shown to express adiponectin, although the func-
tion of the locally-expressed adiponectin remains unclear.
Adiponectin protein was detected in endothelial cells of portal
vessels and liver sinusoids of patients with steatosis23. Bone-
forming cells also expressed adiponectin22. Cultured human
osteoblasts have increased adiponectin expression and secre-
tion into the medium during differentiation22. In addition,
adiponectin mRNA levels increased in osteoblasts with treat-
ment of dietary fatty acids22. The expression of adiponectin is
also observed in skeletal muscle24. Inﬂammatory cytokine
treatment induced adiponectin expression in skeletal muscle
both in vivo and in vitro26,27. More interestingly, recent studies
have shown that adiponectin is also expressed in the brain25.
Adiponectin protein localized in the luteinizing hormone,
growth hormone, follicle-stimulating hormone, and thyroid-
stimulating hormone-producing cells in the pituitary gland of
brain, suggesting that locally-expressed adiponectin may
regulate systemic metabolism through CNS25. However, the
physiological roles of CNS-expressed adiponectin remain to be
elucidated. It should be pointed out that despite the fact that
adiponectin gene expression has been identiﬁed in some non-
adipose tissues, the remarkably high levels of adiponectin
expression and protein secretion rate in adipocytes indicate
that adipose tissue plays a dominant role in maintaining
adiponectin concentrations in the circulation.4. Adiponectin and diseases
Adiponectin circulates at very high concentrations in humans
and mice. It accounts for up to 0.05% of total plasma
protein1,11. Unlike other adipokines whose concentrations
increase with the expansion of fat tissue mass, adiponectin
gene expression and circulating levels are inversely correlated
with adiposity1. Furthermore, a reduction in the body weight
of obese subjects increases plasma adiponectin concentrations,
suggesting that obesity-associated hypoadiponectinemia is
reversible28.
Adiponectin increases insulin sensitivity in various tissues28.
The main mechanism by which adiponectin enhances insulin
sensitivity appears to be due to improved lipid and glucose
metabolism29–33. When globular adiponectin was overex-
pressed in leptin-deﬁcient mice, insulin resistance was amelio-
rated and the expression levels of genes related to fatty acid
oxidation were increased in skeletal muscle34. Another study
showed that transgenic mice with a deletion in the collagenous
domain of adiponectin displayed substantially increased
levels of full-length, oligomeric adiponectin complexes35.
These mice had increased lipid clearance and improved
hepatic insulin sensitivity, which may be associated with
increased 50-AMP-activated protein kinase (AMPK) activity
in the liver35.
Circulating adiponectin levels are decreased in patients with
cardiovascular disease, and epidemiological studies indicated that
low levels of adiponectin are a predictor of the later development
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levels are negatively correlated with plasma TGs, low-density
lipoprotein cholesterol, and were positively correlated with high-
density lipoprotein cholesterol, independent of body mass
index38,39. In addition, epidemiological studies reproducibly indi-
cated that serum adiponectin concentrations were negatively
correlated with vascular inﬂammatory markers and manifestations
of ﬁbrinogen, hypertension, and endothelial dysfunction40–42.
These ﬁndings suggest that there is a close association of
adiponectin with cardiovascular diseases.
Tissue inﬂammation has been well known for its association
with multiple diseases including alcoholic and non-alcoholic
fatty liver disease. A primary systemic marker of tissue
inﬂammation is C-reactive protein (CRP)43. CRP levels in
the circulation are inversely related to serum adiponectin
levels43. In addition, hypoadiponectinaemia is associated with
nonalcoholic hepatic steatosis in obese subjects44, and adipo-
nectin has been shown to have anti-inﬂammatory effects in the
liver and reduces steatosis and hepatomegaly in mouse models
of alcoholic and non-alcoholic fatty liver disease45.
Adiponectin also plays a role in the development and
progression of several obesity-related malignancies. In vivo
studies indicate that circulating levels of adiponectin are
negatively associated with the risk of malignancies associated
with obesity and insulin resistance, which include endometrial
cancer, postmenopausal breast cancer, leukemia, and colon
cancer, gastric cancer, and prostate cancer46–51.
Underlying mechanisms that may link adiponectin with
carcinogenesis include indirect effects via modifying hormone
and cytokine levels such as insulin and tumor necrosis factor a
(TNFa), and direct effects through inhibiting mitogenic
growth factors related to cell proliferation52. Therefore, it
has been generally accepted that adiponectin is a hormone
involved in reducing the risk of obesity-related diseases.5. Adiponectin signaling
Several plasma membrane proteins have been proposed as
adiponectin receptors7,53. A human skeletal muscle library was
screened and a single cDNA that encodes a protein now
called adiponectin receptor 1 (AdipoR1) was ﬁrst revealed.
Database screening further discovered the second adiponectin
receptor (AdipoR2) which is derived from a distinct gene7.
AdipoR1 is ubiquitously expressed, with the most abundance
in skeletal muscle, whereas AdipoR2 is mainly expressed
in the liver. Although both AdipoR1 and R2 have multiple
transmembrane domains, they are not G-protein coupled
receptor7. Furthermore, in contrast to the topology of classical
G-protein coupled receptors, the N-terminal region is
intracellular and the C-terminal region of AdipoR is extra-
cellular7. AdipoR1 has a high afﬁnity with globular adipo-
nectin, but a low afﬁnity with full-length adiponectin, whereas
AdipoR2 has an intermediate afﬁnity with both full length
and globular adiponectin7. Studies show that APPL1 (adaptor
protein, phosphotyrosine interaction, PH domain and leucine
zipper containing 1) binds to the intracellular domain
of both AdipoRs and mediates some of the actions of
adiponectin54,55. AMPK can be activated by adiponectin and
is another downstream protein in the adiponectin signaling
cascade7,8,56.6. Adiponectin regulates lipid metabolism in skeletal muscle
6.1. Adiponectin enhances fatty acid oxidation in skeletal
muscle
Increased fatty acid oxidation is amongst the initially identiﬁed
metabolic effects of adiponectin, and has been considered an
important mechanism through which adiponectin increases insulin
sensitivity. Studies have suggested that activation of AMPK
probably plays an important role in mediating the simulative
effects of adiponectin on fatty acid oxidation8,57. In support of
this, adiponectin treatment increased AMPK phosphorylation and
fatty acid oxidation in the skeletal muscle of mice, whereas
dominant-negative AMPK abolished those effects7,8. In cultured
C2C12 myotubes, adiponectin treatment increased PPARa activ-
ity and its downstream gene expression, such as acyl-CoA oxidase
and carnitinepalmitoyltransferase 157. However, inhibition of
either AMPK or p38 MAPK (mitogen-activated protein kinase)
attenuated the effects of adiponectin on fatty acid oxidation and
PPARg target gene expression. Furthermore, while an AMPK
inhibitor inhibited the activation of p38 MAPK, a p38 MAPK
inhibitor had no effect on AMPK activation. This study clearly
reveled that adiponectin induces fatty acid oxidation in muscle
cells through the sequential activation of AMPK, p38 MAPK,
and PPARa57.
Fatty acids are mainly transported and stored as TGs. There
are two pools of fatty acids for oxidative metabolism in skeletal
muscle: circulating TGs and intramyocellular TGs. Lipoprotein
lipase (LPL) acts as a door keeper in tissue fatty acid metabolism
by hydrolyzing blood TGs58. LPL catalyzes TGs in chylomicrons
and very low density lipoprotein (VLDL) particles, thereby
providing non-esteriﬁed fatty acids and 2-monoacylglycerol for
tissue utilization58. Besides its effects on fatty acid oxidation,
adiponectin appears to increase VLDL-TG catabolism in skeletal
muscle. Fasting plasma TG levels were signiﬁcantly decreased in
mice with elevated adiponectin in circulation59. Interestingly, the
TG-lowering effect of adiponectin was not due to a reduction in
hepatic VLDL-TG secretion, but rather was due to VLDL-TG
catabolism through an increase in postheparin plasma lipoprotein
lipase (LPL) activity. Adiponectin overexpression did not alter
LPL expression and activity in mouse WAT, liver, and heart.
However, skeletal muscle LPL activity as well as its gene
expression level was increased by 41% after viral vector-mediated
increase in blood adiponectin59. The effect of adiponectin on LPL
has been shown in other studies. Human studies indicate that
plasma adiponectin levels are positively associated with posthe-
parin LPL activity60,61. It was also reported that adiponectin
increased TG clearance by increasing LPL expression in WAT in
female adiponectin transgenic mice35. Furthermore, adiponectin
overexpression also increased the gene expression of VLDL
receptor, an important factor for VLDL-TG catabolism, in
skeletal muscle59. These results suggest that adiponectin increases
VLDL catabolism in skeletal muscle, which should provide fatty
acids as substrates for oxidation59. However, it is still unknown
whether adiponectin alters intramyocellular TG mobilization.6.2. Adiponectin stimulates mitochondrial biogenesis
in skeletal muscle
Mitochondria are cellular power plants that convert metabo-
lites of nutrients into ATP. It has been reported that subjects
Bonggi Lee, Jianhua Shao338with insulin resistance or type 2 diabetes have reduced
mitochondrial content62 and decreased electron transport
chain activity in total62,63, intramyoﬁbular, and subsarcolemal
mitochondria64. In addition to mitophagy and mitochondrial
fusion and ﬁssion, biogenesis is important in maintaining
mitochondrial content. Recently, the stimulative effects of
adiponectin on mitochondrial biogenesis in skeletal muscle
have been highlighted. Animal studies indicate that adiponec-
tin increases mitochondrial biogenesis and oxidative capacity
in skeletal muscle65,66. Activated AMPK and increased per-
oxisome proliferator-activated receptor g coactivator1 a
(PGC1 a) have been suggested to mediate the regulatory
effects of adiponectin on mitochondrial biogenesis and func-
tion8,57,65,67. In addition, muscle-speciﬁc AdipoR1 knockout
mice exhibited insulin resistance at least partially due to a
reduction in mitochondrial content and activity in skeletal
muscle65. Those results demonstrate that adiponectin and/or
adiponectin signaling plays an indispensible role in regulating
mitochondrial biogenesis and function in mice.
A human study also supports the roles of adiponectin in
mitochondrial biogenesis in skeletal muscle67. The relationship
between adiponectin and mitochondrial function was investi-
gated in muscle from humans who were predisposed to type 2
diabetes. Individuals with a family history of type 2 diabetes
exhibit skeletal muscle insulin resistance and mitochondrial
dysfunction. In addition, adiponectin levels strongly correlate
with mitochondrial DNA content in human skeletal muscle67.
Furthermore, treatment of primary cultured human myotubes
with adiponectin resulted in increased mitochondrial biogen-
esis, palmitate oxidation, and citrate synthase activity, and
reduced the production of reactive oxygen species67. On the
other hand, knocking down AdipoR1, R2, or both by siRNA
inhibited adiponectin-mediated effects on mitochondrial func-
tion67. These data demonstrate that adiponectin enhances
mitochondrial biogenesis and oxidative metabolism in the
skeletal muscle.6.3. Underlying mechanisms through which adiponectin
enhances mitochondrial biogenesis and improves lipid
metabolism in skeletal muscle
PGC-1a is a transcriptional coactivator and is well known for
its role in controlling mitochondrial biogenesis65,68. The PGC-1a
gene expression is regulated by various physiological stimula-
tions and molecular factors. Of those, in response to exercise,
PGC-1a is partially up-regulated by Ca2þ signaling through
molecules such as Ca2þ/calmodulin-dependent protein kinase
(CaMK) in skeletal muscle69. Interestingly, adiponectin sti-
mulates Ca2þ inﬂux via AdipoR1, thereby activating Ca2þ/
calmodulin-dependent protein kinase kinase (CAMKK)b,
which is an upstream signal of CaMK65. These events induced
PGC-1a expression. Furthermore, adiponectin stimulates expres-
sion of SIRT1, which deacetylates and activates PGC-1a,
indicating that adiponectin stimulates both PGC-1a expression
and activation65. In contrast, muscle-speciﬁc AdipoR1 knockout
abolished the adiponectin-induced increase in intracellular Ca2þ
inﬂux and activation of CaMKK, AMPK, and SIRT165.
Furthermore, muscle-speciﬁc AdipoR1 knockout mice exhibited
reduced PGC1a expression, increased PGC-1a acetylation, and
decreased mitochondrial count and activity in skeletal muscle65.
These results indicate that adiponectin/AdipoR1 regulatemitochondrial biogenesis and function through Ca2þand
AMPK/SIRT1 dependent mechanisms65.
There are other pathways that can also activate PGC-1a or
mediate the simulative effects of adiponectin on mitochondrial
biogenesis. p38 MAPK is a downstream signal in the adipo-
nectin pathway7,55,70. Activation of p38 MAPK increases not
only PGC-1a expression but also its activity71–73. Inhibition of
p38 MAPK completely blocks Ca2þ-induced PGC-1a expres-
sion74. These results indicate that p38 MAPK plays an indis-
pensible role in mediating adiponectin-stimulated PGC-1a
expression, activation, and mitochondrial biogenesis in skeletal
muscle.
It has been well reported that adiponectin induces p38
MAPK activation. Similar to other MAPK members, p38
MAPK is activated by MAPK kinase (MKK)-mediated
phosphorylation, and is deactivated by MAPK phosphatase
(MKP)-catalyzed de-phosphorylation75. Therefore, p38 MAPK
activity is determined by the counterbalance of MKKs and
MKPs70. APPL1 has been shown to selectively transduce
signals from the adiponectin receptor to the TGFb-activated
kinase1-MAPK kinase (MKK) 3/p38 MAPK pathway70. Our
recent study further investigated how adiponectin induces p38
MAPK and its downstream activation66. In addition to the
involvement of MKK, our study also found that adiponectin
reduces the protein levels of MKP1 in mouse skeletal muscle66.
Furthermore, MKP1 overexpression attenuated adiponectin-
enhanced PGC-1a gene expression and mitochondrial biogen-
esis in C2C12 myotubes66. Knocking down MKP1 protein
expression led to enhanced p38 MAPK activation and to
higher PGC-1a expression and mitochondrial biogenesis in
skeletal muscle66. These results indicate that the suppression of
MKP1 expression is one of the underlying mechanisms
through which adiponectin stimulates p38 MAPK/PGC-1a
signaling and mitochondrial biogenesis in skeletal muscle66.7. Summary
Adiponectin is an adipocyte-secreted hormone that improves
lipid and glucose metabolism. In addition to the insulin
sensitizing effect, adiponectin directly enhances fatty acid
oxidation in skeletal muscle through its own signaling or
other pathways including p38 MAPK/PGC-1a. Although
adiponectin stimulates mitochondrial biogenesis in skeletal
muscle, it is still largely unknown how adiponectin increases
mitochondrial oxidative metabolism.
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